Copyright © 2000 by the European Society of Cardiology.
Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide)
Department of Medicine, Ruhr-University Knappschafts-Krankenhaus, Bochum, Germany
revised June 7, 1999; accepted June 9, 1999
Abstract
Aims Sulfonylureas may interfere with ‘ischaemic preconditioning’ and worsen the prognosis in diabetic patients with acute myocardial infarction.
Methods and Results Three hundred and fifty-seven non-diabetic patients admitted with acute myocardial infarction to one hospital over 6·5 years (72 deaths, in-hospital mortality 20·2%) were compared to 245 Type 2 diabetic patients categorized as having taken sulfonylureas (glibenclamide 7±3mg.day–1; n=76, 25 deaths=32·9%;P=0·025), not having taken sulfonylureas (n=89, 29 deaths=33·0%;P=0·012), and newly diagnosed as having diabetes (n=80, 20 deaths=25·0%). Survival was significantly different (log-rank test: P=0·03). Increments in creatine kinase and creatine kinaseMBactivity were higher in non-diabetic patients (P<0·01).
Conclusions In-hospital mortality in Type 2 diabetic patients is higher than in non-diabetic patients suffering acute myocardial infarction regardless of whether or not they had been treated with sulfonylureas. Glibenclamide does not enlarge myocardial necroses.
Key Words: Sulfonylureas, ischemic preconditioning, myocardial infarction, mortality, Type 2 diabetes
f1 Correspondence: Prof. Dr med. Michael A. Nauck, Medizinische Universitätsklinik, Ruhr-Universität Bochum, Knappschafts-Krankenhaus, In der Schornau 23-25, D-44892 Bochum, Germany.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. E. Inzucchi and D. K. McGuire New Drugs for the Treatment of Diabetes: Part II: Incretin-Based Therapy and Beyond Circulation, January 29, 2008; 117(4): 574 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Misaki, X. Mao, Y.-F. Lin, S. Suga, G.-H. Li, Q. Liu, Y. Chang, H. Wang, M. Wakui, and J. Wu Iptakalim, a Vascular ATP-Sensitive Potassium (KATP) Channel Opener, Closes Rat Pancreatic beta-Cell KATP Channels and Increases Insulin Release J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 871 - 878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Valensi and G. Slama Review: Sulphonylureas and cardiovascular risk: facts and controversies The British Journal of Diabetes & Vascular Disease, July 1, 2006; 6(4): 159 - 165. [Abstract] [PDF]
|
|
|
|
 |
|
 Z. T. Bloomgarden Cardiovascular Disease Diabetes Care, May 1, 2006; 29(5): 1160 - 1166. [Full Text] [PDF]
|
|
|
|
|
|
J. J. Meier, S. Deifuss, A. Klamann, V. Launhardt, W. H. Schmiegel, and M. A. Nauck Plasma Glucose at Hospital Admission and Previous Metabolic Control Determine Myocardial Infarct Size and Survival in Patients With and Without Type 2 Diabetes: The Langendreer Myocardial Infarction and Blood Glucose in Diabetic Patients Assessment (LAMBDA) Diabetes Care, October 1, 2005; 28(10): 2551 - 2553. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Kimmel and S. E. Inzucchi Oral Agents for Type 2 Diabetes: An Update Clin. Diabetes, April 1, 2005; 23(2): 64 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Clement, S. S. Braithwaite, M. F. Magee, A. Ahmann, E. P. Smith, R. G. Schafer, and I. B. Hirsch Management of Diabetes and Hyperglycemia in Hospitals Diabetes Care, February 1, 2004; 27(2): 553 - 591. [Full Text] [PDF]
|
|
|
|
 |
|
 J J Meier, B Gallwitz, W E Schmidt, A Mugge, and M A Nauck Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart, January 1, 2004; 90(1): 9 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-M. Lee, S.-F. Su, T.-F. Chou, and C.-H. Tsai Pharmacologic preconditioning of estrogen by activation of the myocardial adenosine triphosphate-sensitive potassium channel in patients undergoing coronary angioplasty J. Am. Coll. Cardiol., March 6, 2002; 39(5): 871 - 877. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. O. Farouque, S. G. Worthley, I. T. Meredith, R. A. P. Skyrme-Jones, and M. J. Zhang Effect of ATP-Sensitive Potassium Channel Inhibition on Resting Coronary Vascular Responses in Humans Circ. Res., February 8, 2002; 90(2): 231 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z S Kyriakides, S Psychari, N Chrysomallis, M Georgiadis, E Sbarouni, and D T Kremastinos Type II diabetes does not prevent the recruitment of collateral vessels and the normal reduction of myocardial ischaemia on repeated balloon inflations during angioplasty Heart, January 1, 2002; 87(1): 61 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Weih, N. Amberger, S. Wegener, U. Dirnagl, T. Reuter, and K. Einhaupl Sulfonylurea Drugs Do Not Influence Initial Stroke Severity and In-Hospital Outcome in Stroke Patients With Diabetes Stroke, September 1, 2001; 32(9): 2029 - 2032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Spallarossa, M. Schiavo, P. Rossettin, S. Cordone, L. Olivotti, R. Cordera, and C. Brunelli Sulfonylurea Treatment of Type 2 Diabetic Patients Does Not Reduce the Vasodilator Response to Ischemia Diabetes Care, April 1, 2001; 24(4): 738 - 742. [Abstract] [Full Text]
|
|
|
|
 |
|
 D.J. Betteridge and L. Close Diabetes, coronary heart disease and sulphonylureas--not the final word Eur. Heart J., May 2, 2000; 21(10): 790 - 792. [PDF]
|
|
|
|
|
|
H. M. O. Farouque, S. G. Worthley, I. T. Meredith, R. A. P. Skyrme-Jones, and M. J. Zhang Effect of ATP-Sensitive Potassium Channel Inhibition on Resting Coronary Vascular Responses in Humans Circ. Res., February 8, 2002; 90(2): 231 - 236. [Abstract] [Full Text] [PDF]
|
|